In yesterday’s Wall Street session, Xenon Pharmaceuticals Inc (NASDAQ:XENE) shares traded at $43.15, up 1.65% from the previous session.
XENE stock price is now 4.31% away from the 50-day moving average and 4.26% away from the 200-day moving average. The market capitalization of the company currently stands at $3.29B.
On October 01, 2024, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $53, while ‘Citigroup’ rates the stock as ‘Buy’
In other news, PATOU GARY, Director sold 4,891 shares of the company’s stock on Nov 22 ’24. The stock was sold for $200,947 at an average price of $41.08. Upon completion of the transaction, the Director now directly owns 23,573 shares in the company, valued at $1.02 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 22 ’24, Director GARY PATOU bought 4,891 shares of the business’s stock. A total of $200,932 was incurred on buying the stock at an average price of $41.08. A total of 3.88% of the company’s stock is owned by insiders.
During the past 12 months, Xenon Pharmaceuticals Inc has had a low of $29.00 and a high of $50.99. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 22.21, and a quick ratio of 22.21. The fifty day moving average price for XENE is $41.3072 and a two-hundred day moving average price translates $41.4116 for the stock.
The latest earnings results from Xenon Pharmaceuticals Inc (NASDAQ: XENE) was released for 2024-06-30. The company reported revenue of $73.68 million for the quarter, compared to $55.68 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 32.31 percent.
